BRISBANE, Calif., April 26 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that it will release first quarter 2007 financial results on Thursday, May 3, 2007 at 4:00 p.m. EDT. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. EDT that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 7427687. To access the webcast, please log on to the Company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642- 1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 7427687.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com .
InterMune, Inc.CONTACT: investors, Jim Goff of InterMune, Inc., +1-415-466-2228, orjgoff@intermune.com
Web site: http://www.intermune.com//
